Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 1, 2012, Pages 103-112

  Pithavala, Yazdi K ^a   Chen, Ying ^a   Toh, Melvin ^a   Selaru, Paulina ^a   LaBadie, Robert R ^a   Garrett, May ^a   Hee, Brian ^a   Mount, Janessa ^a   Ni, Grace ^a   Klamerus, Karen J ^a   Tortorici, Michael A ^a  

^a PFIZER INC   (United States)

Author keywords

Axitinib; Axitinib Form IV FCIR; Axitinib Form XLI FCIR; Food effects; Formulation; Pharmacokinetics

Indexed keywords

AXITINIB;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; FEMALE; FILM COATING; FLATULENCE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; CROSS-OVER STUDIES; DIARRHEA; DIETARY FATS; ENERGY INTAKE; FASTING; FATIGUE; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; IMIDAZOLES; INDAZOLES; MALE; MIDDLE AGED; NAUSEA; TABLETS; YOUNG ADULT;

EID: 84863455515     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1888-9     Document Type: Article

References (19)

1. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283
2. Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ (2010) Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 65:563-570
3. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975-984 (Pubitemid 47629888)
4. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
5. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J (2009) Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27:3836-3841
6. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483
7. US Department of Health and Human Services Food and Drug Administration (2002) Guidance for industry: food-effect bioavailability and fed bioequivalence studies. In: (CDER) CfDEaR (ed) Office of Training and Communications, Division of Drug Information, Rockville, HFD-240
8. Pithavala YK, Tong W, Mount J, Rahavendran SV, Garrett M, Hee B, Selaru P, Sarapa N, Klamerus KJ (2012) Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 30:273-281
9. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181 (Pubitemid 36962641)
10. Singh BN (1999) Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213-255
11. Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner ER, Figg WD, Sparreboom A (2008) Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 19:275-281
12. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol 63:1049-1063
13. Berlin J, Tutsch KD, Arzoomanian RZ, Alberti D, Binger K, Feierabend C, Dresen A, Marnocha R, Pluda J, Wilding G (2002) Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food. Clin Cancer Res 8:86-94 (Pubitemid 34101462)
14. Valle M, Di Salle E, Jannuzzo MG, Poggesi I, Rocchetti M, Spinelli R, Verotta D (2005) A predictive model for exemestane pharmacokinetics/ pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol 59:355-364 (Pubitemid 40388090)
15. Furlanut M, de Manzoni G, Pasini F, Tasselli S, Tomezzoli A, Poz D, Franceschi L (2007) Daunorubicin and daunorubicinol tissue concentrations in gastric cancer patients after local administration of a liposomal preparation. Pharmacol Res 56:344-349 (Pubitemid 47488902)
16. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4462-4468
17. Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL (2010) A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 21:297-304
18. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371:2101-2108
19. Fleisher D, Li C, Zhou Y, Pao LH, Karim A (1999) Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233-254 (Pubitemid 29178760)